Completed PHASE3 INTERVENTIONAL 2-arm NCT05634746

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis

Sponsor: Ellodi Pharmaceuticals, LP

Conditions Eosinophilic Esophagitis

Interventions APT-1011 Esophagogastroduodenoscopy Placebo oral tablet

Updated 19 times since 2023 Last updated: Aug 11, 2025 Started: Dec 29, 2022 Primary completion: Aug 12, 2024 Completion: Aug 12, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05634746, this PHASE3 trial focuses on Eosinophilic Esophagitis and remains completed. Sponsored by Ellodi Pharmaceuticals, LP, it has been updated 19 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Oct 2024 — Sep 2025 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 14 earlier versions

May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Apr 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Feb 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ellodi Pharmaceuticals, LP

Data source: Ellodi Pharmaceuticals, LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Bellevue, United States , Boston, United States , Bozeman, United States , Camarillo, United States , Chapel Hill, United States , Charlotte, United States , Chesterfield, United States , Chevy Chase, United States , Cincinnati, United States and 47 more locations